Title : Recombinant human acid sphingomyelinase as an adjuvant to sorafenib treatment of experimental liver cancer.

Pub. Date : 2013

PMID : 23724146






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 METHODOLOGY/PRINCIPAL FINDINGS: In vitro, rhASM/sorafenib treatment reduced the viability of Huh7 liver cancer cells more than sorafenib. Sorafenib MIR7-3 host gene Homo sapiens
2 CONCLUSIONS/SIGNIFICANCE: The rhASM/sorafenib combination exhibited a synergistic effect on reducing the tumor volume and blood vessel density in Huh7 xenografts, despite modest activity of rhASM in these tumors. Sorafenib MIR7-3 host gene Homo sapiens